These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23910587)

  • 1. Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction.
    Joyce E; Mulroy E; Scott J; Melling J; Goggin C; McGorrian C; O'Rourke K; Lynch T; Mahon N
    J Card Fail; 2013 Aug; 19(8):571-6. PubMed ID: 23910587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
    Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis.
    Pattoneri P; Sozzi F; Pelà G; Montanari E; Moruzzi P; Borghetti A; Cappellini MD
    Echocardiography; 2009 Apr; 26(4):397-402. PubMed ID: 19017314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
    Mulroy E; Joyce E; Scott J; Melling J; Goggin C; Mahon N; O'Rourke K; Lynch T
    Eur Neurol; 2012; 67(1):45-7. PubMed ID: 22156316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis.
    Spindler M; Weilbach F; Beer M; Sandstede J; Köstler H; Strotmann J; Voelker W; Hahn D; Ertl G; Gold R
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):680-7. PubMed ID: 14576518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tei-index in patients with mild-to-moderate congestive heart failure.
    Bruch C; Schmermund A; Marin D; Katz M; Bartel T; Schaar J; Erbel R
    Eur Heart J; 2000 Nov; 21(22):1888-95. PubMed ID: 11052862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do female patients with metabolic syndrome have masked left ventricular dysfunction?
    Dursunoğlu D; Evrengül H; Tanriverdi H; Kuru O; Gür S; Kaftan A; Kiliç M
    Anadolu Kardiyol Derg; 2005 Dec; 5(4):283-8. PubMed ID: 16330393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicity.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Montanari A
    Heart Asia; 2012; 4(1):91-4. PubMed ID: 27326038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.
    Luchowski P; Mitosek-Szewczyk K; Bartosik-Psujek H; Rubaj A; Jankiewicz M; Wojczal J; Szczepańska-Szerej A; Stelmasiak Z
    Clin Neurol Neurosurg; 2009 Oct; 111(8):676-8. PubMed ID: 19632767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography.
    Ha JW; Lee HC; Kang ES; Ahn CM; Kim JM; Ahn JA; Lee SW; Choi EY; Rim SJ; Oh JK; Chung N
    Heart; 2007 Dec; 93(12):1571-6. PubMed ID: 17449503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chronic fluorosis on left ventricular diastolic and global functions.
    Varol E; Akcay S; Ersoy IH; Koroglu BK; Varol S
    Sci Total Environ; 2010 May; 408(11):2295-8. PubMed ID: 20206377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diastolic functions and myocardial performance index in obese patients with or without metabolic syndrome: a tissue Doppler study.
    Koç F; Tokaç M; Kaya C; Kayrak M; Yazıcı M; Karabağ T; Vatankulu MA; Ayhan S; Demir K
    Turk Kardiyol Dern Ars; 2010 Sep; 38(6):400-4. PubMed ID: 21200118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of left ventricular diastolic function and the Tei index by tissue Doppler imaging in patients with primary hyperparathyroidism.
    Baykan M; Erem C; Erdogan T; Ersöz HO; Gedikli O; Korkmaz L; Kücükosmanoglu M; Haclhasanoglu A; Kaplan S; Celik S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):483-8. PubMed ID: 17371463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.
    Zingler VC; Nabauer M; Jahn K; Gross A; Hohlfeld R; Brandt T; Strupp M
    Eur Neurol; 2005; 54(1):28-33. PubMed ID: 16088176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diastolic function abnormalities in rheumatoid arthritis: relation with duration of disease.
    Udayakumar N; Venkatesan S; Rajendiran C
    Singapore Med J; 2007 Jun; 48(6):537-42. PubMed ID: 17538753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
    Buttmann M; Seuffert L; Mäder U; Toyka KV
    Neurology; 2016 Jun; 86(23):2203-7. PubMed ID: 27170571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
    Kingwell E; Koch M; Leung B; Isserow S; Geddes J; Rieckmann P; Tremlett H
    Neurology; 2010 Jun; 74(22):1822-6. PubMed ID: 20427751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.